Kairos Pharma Ltd. (NYSE American: KAPA) presented interim efficacy results for its lead candidate ENV-105 at the 11th International Conference on Cancer Research & Drug Development in Houston on Nov. 3, 2026. The data, delivered by President and Chief Scientific Officer Neil Bhowmick, showed a statistically significant improvement in median progression-free survival (PFS) for patients receiving ENV-105 plus apalutamide compared with apalutamide alone in metastatic castration-resistant prostate cancer (mCRPC). The median PFS was 17.7 months versus two months, respectively (P=0.0008). This result is important because it suggests that targeting CD105, a protein linked to drug resistance and relapse, may restore sensitivity to standard therapies and potentially extend the time before disease progression.
ENV-105 is a first-in-class CD105/BMP signaling inhibitor being evaluated in a Phase 1 trial for EGFR-driven non-small cell lung cancer and a Phase 2 trial in combination with apalutamide for mCRPC. Based on the interim analysis, the Phase 2 trial will now focus on first-line therapy after enzalutamide, incorporating first-line resistance in a larger patient group. Previous preclinical research has also shown that ENV-105 may enhance radiation sensitivity in prostate cancer models. Bhowmick said the findings support the company’s hypothesis that targeting CD105 may interrupt mechanisms of treatment resistance and restore sensitivity to established cancer therapies.
The implications for patients and the oncology field are notable. If confirmed in larger studies, ENV-105 could offer a new strategy for overcoming resistance to existing treatments, a major challenge in prostate cancer and other malignancies. Kairos Pharma, based in Los Angeles, California, is focused on using structural biology to overcome drug resistance and immune suppression in cancer. Its lead candidate ENV-105 is an antibody that targets CD105, which the company identifies as a key driver of resistance and disease relapse. By aiming to reverse drug resistance, ENV-105 could help extend the effectiveness of standard therapies across multiple cancer types.
For investors and industry observers, the interim data provide a potential catalyst for Kairos Pharma. The company’s NYSE American listing under the ticker KAPA makes it accessible to public market investors. The full press release can be viewed at https://ibn.fm/PIrky, and the latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA. Additional information about Kairos Pharma (NYSE American: KAPA) is available through TinyGems, a communications platform focused on small-cap and mid-cap companies. TinyGems is part of the Dynamic Brand Portfolio at IBN, which provides wire solutions via InvestorWire and other services. The platform also offers editorial syndication to 5,000+ outlets and social media distribution to help companies reach a wide audience. These channels may help disseminate future updates on ENV-105 as the clinical program advances.
The interim Phase 2 results are a key milestone for Kairos Pharma and for the broader effort to address drug resistance in cancer. The statistically significant PFS improvement, if replicated, could position ENV-105 as a valuable addition to treatment regimens for mCRPC and potentially other cancers. However, the data are interim and from a relatively small patient group, so further trials will be needed to confirm the findings. Investors and patients should watch for additional results as the trial expands to first-line therapy after enzalutamide. For full terms and disclaimers regarding TinyGems content, see https://www.TinyGems.com/Disclaimer.
